Trabecular bone sc0re in XXXX with liver transplants after one year of @entity562 treatment.

@entity1 @entity174 @entity3875 @entity170 @entity2331 @entity562 @entity460 @entity14764
OBJECTIVE: The aim of this study was to analyze the effect of @entity562 on Trabecular Bone Score in liver transplant @entity1 with low bone mass, during one year follow-up. METHODS: In this retrospective cohort study, @entity14764 was calculated from Dual X-ray absorptiometry images of the lumbar spine (LS), collected from a prospective randomized open-label 1 year trial performed in liver recipient @entity1 . 89 @entity1 with @entity2331 or @entity170 were randomized to receive RIS plus @entity460 and @entity3875 or @entity460 and @entity3875 . RESULTS: @entity14764 was low in both groups at baseline, 6 and 12 months. Baseline @entity14764 at the LS showed degraded microarchitecture in 22.8 % of @entity1 , partially degraded in 40.3%, and normal values in 36.8% of the @entity1 . After one year of treatment no difference in @entity14764 was observed between both groups. No correlations were found between BMD and @entity14764 values at any follow-up time point. No relationship was found between BMD, @entity14764 or immunosuppressive drugs with incidental @entity174 . CONCLUSION: No significant effect in @entity14764 was observed in liver transplant @entity1 treated with RIS or @entity460 and @entity3875 after 1 year of follow-up. In these @entity1 the clinical usefulness of this new tool should be established. This article is protected by copyright. All rights reserved.
